IQVIA Releases Global Oncology Trends Study
The IQVIA Institute for Human Data Science released its latest report, Global Oncology Trends 2019: Therapeutics, Clinical Development and Health System Implications. The report found that 15 new active substance (NAS) oncology treatments with 17 indications, including one tissue-agnostic therapy, launched in the U.S. in 2018-which is a record. Those 2018 debuts bring the total number of new oncology therapeutics launched since 2013 to 57 covering 89 approved indications for 23 different tumor types.
In addition to detailing the influx of new oncology drugs within the R&D pipeline and marketplace, the Institute report explores health system barriers hindering the realization of the benefits of those therapies and drug candidates. The report further notes that despite extensive pipeline activity, oncology remains the most challenging area for research and development, facing significant risk of failure and long, costly development.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
